Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

13 hours ago 5

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.

Read Entire Article

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

Related

UBS says savings from Credit Suisse deal reach $9.1 billion ...

Here’s how much today’s 65-year-olds will spend on healthcar...

Social Security wants to make a change that would cause 3.4 ...

Trending

Popular

Ether emerges as winner after crypto’s ‘watershed moment’: B...

Social Security agency agrees to customer-service audit afte...

Why is IBM’s stock down after an earnings beat? Here’s one q...

Crypto 'control' takes center stage at Roman Storm...

SOL price drop to $180 would be 'golden' entry bef...